[1]樊丽壮,王 博,徐爱兰,等.血浆循环游离DNA含量及完整性在乳腺癌中的临床价值[J].医学信息,2023,36(01):107-112.[doi:10.3969/j.issn.1006-1959.2023.01.021]
　FAN Li-zhaung,WANG Bo,XU Ai-lan,et al.Clinical Value of Plasma Circulating Cell-free DNA Content and Integrity in Breast Cancer[J].Journal of Medical Information,2023,36(01):107-112.[doi:10.3969/j.issn.1006-1959.2023.01.021]
点击复制

血浆循环游离DNA含量及完整性在乳腺癌中的临床价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年01期
页码:
107-112
栏目:
论著
出版日期:
2023-01-01

文章信息/Info

Title:
Clinical Value of Plasma Circulating Cell-free DNA Content and Integrity in Breast Cancer
文章编号:
1006-1959（2023）01-0107-06
作者:
樊丽壮; 王 博; 徐爱兰; 等
（佳木斯大学附属第一医院肿瘤科，黑龙江 佳木斯 154000）
Author(s):
FAN Li-zhaung; WANG Bo; XU Ai-lan; et al.
(Department of Oncology,the First Affiliated Hospital of Jiamusi University,Jiamusi 154000,Heilongjiang,China)
关键词:
乳腺癌; 循环游离DNA; 淋巴结转移
Keywords:
Breast cancer; Circulating cell-free DNA; Lymphatic metastasis
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2023.01.021
文献标志码:
A
摘要:
目的 探讨外周血中循环游离DNA（cf-DNA）含量和完整性在乳腺癌辅助诊断中的临床价值。方法 收集2020年9月-2021年7月于我院就诊的56例乳腺癌患者血液样本设为病例组和体检中心20名健康体检健康人血样设为对照组。采用实时荧光定量PCR检测血液样本中cf-DNA含量和完整性，以长、短片段（241、100 bp）扩增产物比值作为cf-DNA完整性指标，并结合其临床病理特性进行分析。应用ROC曲线分析cf-DNA含量和完整性对乳腺癌辅助诊断的敏感度与特异度。应用Fisher检验分析乳腺癌患者临床病理参数与cf-DNA完整性的关系。结果 病例组长、短片段血浆cf-DNA含量高于对照组，差异有统计学意义（P＜0.05）；病例组血浆cf-DNA完整性水平高于对照组，但差异无统计学意义（P＞0.05）；ROC曲线分析显示，长、短片段含量及完整性的曲线下面积分别是0.79、0.99、0.59，敏感度分别是70.00%、100.00%、44.46%，特异度分别是90.00%、95.00%、85.00%。构建成β-actin及长、短片段质粒标准品的扩增曲线，β-actin标准曲线的线性决定系数（R2）=0.9583，扩增效率达93.40%；短片段标准曲线的线性决定系数R2=0.8745，扩增效率达91.70%；长片段标准曲线的线性决定系数R2=0.9695，扩增效率达99.30%。无淋巴结转移乳腺癌患者血浆cf-DNA完整性低于有淋巴结转移的乳腺癌患者，差异有统计学意义（P＜0.05）。结论 血浆cf-DNA含量和完整性可以作为乳腺癌辅助诊断的潜在生物学指标，且cf-DNA完整性中可提高乳腺癌患者的诊断率。同时，淋巴结转移与cf-DNA完整性相关，可以检测其完整性以区分淋巴结是否转移。
Abstract:
Objective To investigate the clinical value of circulating-free cell DNA (cf-DNA) content and integrity in the diagnosis of breast cancer.Methods From September 2020 to July 2021, 56 blood samples of breast cancer patients in our hospital were collected as patient group and 20 blood samples of healthy people in physical examination center as normal group. The content and integrity of cf-DNA in blood samples were detected by real-time fluorescence quantitative PCR. The ratio of amplification products of long and short fragments (241 and 100 bp) was used as an index of cf-DNA integrity, and its clinicopathological characteristics were analyzed. ROC curve was used to analyze the sensitivity and specificity of cf-DNA content and integrity in the diagnosis of breast cancer. Fisher test was used to analyze the relationship between clinicopathological parameters and cf-DNA integrity in breast cancer patients.Results The plasma cf-DNA content of long and short segments in the patient group was higher than that in the normal group, and the difference was statistically significant (P<0.05). The plasma cf-DNA integrity level in the patient group was higher than that in the normal group, but the difference was not statistically significant (P>0.05). ROC curve analysis showed that the area under the curve of long and short segment content and integrity was 0.79, 0.99 and 0.59, respectively, the sensitivity was 70.00%, 100.00% and 44.46%, respectively, and the specificity was 90.00%, 95.00% and 85.00%, respectively. The amplification curve of β-actin, long and short fragment plasmid standard was constructed. The linear determination coefficient (R2) of β-actin standard curve was 0.9583, and the amplification efficiency was 93.40%; the linear coefficient of determination (R2) of the standard curve was 0.8745, and the amplification efficiency was 91.70%; the linear determination coefficient of the long fragment standard curve was R2=0.9695, and the amplification efficiency was 99.30%. The plasma cf-DNA integrity of breast cancer patients without lymph node metastasis was lower than that of breast cancer patients with lymph node metastasis, and the difference was statistically significant (P<0.05).Conclusion Plasma cf-DNA content and integrity can be used as potential biological indicators for auxiliary diagnosis of breast cancer, and cf-DNA integrity can improve the diagnosis rate of breast cancer patients. At the same time, lymph node metastasis is related to cf-DNA integrity, and its integrity can be detected to distinguish lymph node metastasis.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Zejda JE,Kaleta A.Modes of Early Detection of Breast Cancer in Katowice Region,Poland[J].Int J Environ Res Public Health,2020,17(8):2642.[3]Wu HJ,Chu PY.Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer[J].Int J Mol Sci,2021,22(2):636.[4]Kustanovich A,Schwartz R,Peretz T,et al.Life and death ofcirculating cell-free DNA[J].Cancer Biol Ther,2019,20(8):1057-1067.[5]Alix-Panabières C.The future of liquid biopsy[J].Nature,2020,579(7800):S9.[6]Rheinbay E,Parasuraman P,Grimsby J,et al.Recurrent and functional regulatory mutations in breast cancer[J].Nature,2017,547(7661):55-60.[7]Woolston C.Breast cancer: 4 big questions[J].Nature,2015,527(7578):S120.[8]Cristiano S,Leal A,Phallen J,et al.Genome-wide cell-free DNA fragmentation in patients with cancer[J].Nature,2019,570(7761):385-389.[9]Shen SY,Singhania R,Fehringer G,et al.Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J].Nature,2018,563(7732):579-583.[10]Watts G.Liquid biopsy: still early days for early detection[J].Lancet,2018,391(10140):2593-2594.[11]顾益凤,朱自力,张金业,等.乳腺癌中血浆游离DNA含量和完整性的临床应用[J].检验医学,2017,32(8):671-676.[12]Jafari SH,Saadatpour Z,Salmaninejad A,et al.Breast cancer diagnosis: Imaging techniques and biochemical markers[J].J Cell Physiol,2018,233(7):5200-5213.[13]Lannin DR,Wang S.Are Small Breast Cancers Good because They Are Small or Small because They Are Good?[J].N Engl J Med,2017,376(23):2286-2291[14]Yu D,Tong Y,Guo X,et al.Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis[J].Front Oncol,2019,9:95.[15]Pedini P,Graiet H,Laget L,et al.Qualitative and quantitative comparison of cell-free DNA and cell-free fetal DNA isolation by four (semi-)automated extraction methods: impact in two clinical applications: chimerism quantification and noninvasive prenatal diagnosis[J].J Transl Med,2021,19(1):15.[16]Panagopoulou M,Esteller M,Chatzaki E.Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine[J].Cancers (Basel),2021,13(4):728.[17]Miao Y,Fan Y,Zhang L,et al.Clinical value of plasma cfDNA concentration and integrity in breast cancer patients[J].Cell Mol Biol (Noisy-le-grand),2019,65(6):64-72.[18]Moss J,Zick A,Grinshpun A,et al.Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer[J].Ann Oncol,2020,31(3):395-403.[19]Kamel AM,Teama S,Fawzy A,et al.Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer[J].Tumour Biol,2016,37(6):7565-7572.[20]Cao G,Xie Y,Jiang X,et al.Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery[J].Cell Mol Biol (Noisy-le-grand),2019,65(6):44-51.[21]Panagopoulou M,Karaglani M,Balgkouranidou I,et al.Circulating cell-free DNA in breast cancer: size profiling,levels,and methylation patterns lead to prognostic and predictive classifiers[J].Oncogene,2019,38(18):3387-3401.[22]Iqbal S,Vishnubhatla S,Raina V,et al.Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer[J].Springerplus,2015,4:265.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(01):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(01):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Journal of Medical Information,2018,31(01):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘雪静,路 红,徐熠琳,等.乳腺影像与容积导航技术初步应用的临床分析[J].医学信息,2022,35(11):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
　LIU Xue-jing,LU Hong,XU Yi-lin,et al.Clinical Analysis of the Preliminary Application of Breast Imaging and Volume Navigation Technology[J].Journal of Medical Information,2022,35(01):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
[6]刘在波,修文娟.背阔肌皮瓣联合假体在乳腺癌改良根治术后乳房重建中的应用[J].医学信息,2019,32(02):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
　LIU Zai-bo,XIU Wen-juan.Application of Latissimus Dorsi Flap Combined with Prosthesis in Breast Reconstruction after Modified Radical Mastectomy for Breast Cancer[J].Journal of Medical Information,2019,32(01):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
[7]孟庆国,王佳雪,王斯佳.马来酸吡咯替尼对乳腺癌术后患者心脏功能的影响[J].医学信息,2019,32(02):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
　MENG Qing-guo,WANG Jia-xue,WANG Si-jia.Effect of Pyrrolidine Maleate on Cardiac Function in Patients after Breast Cancer Operation[J].Journal of Medical Information,2019,32(01):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
[8]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Journal of Medical Information,2018,31(01):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[9]满枋霖,葛俊宏,林晓月,等.p21活化激酶在乳腺癌中的作用研究[J].医学信息,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
　MAN Fang-lin,GE Jun-hong,LIN Xiao-yue,et al.The Role of p21 Activated Kinase in Breast Cancer[J].Journal of Medical Information,2019,32(01):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
[10]张天竺,宁 勇.长链非编码RNA调控乳腺癌发生发展的研究进展[J].医学信息,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
　ZHANG Tian-zhu,NING Yong.Advances in Research on Long-chain Non-coding RNA Regulation of Breast Cancer Development[J].Journal of Medical Information,2019,32(01):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
[11]樊丽壮,王 博,徐爱兰,等.循环游离DNA的生物特性及其在乳腺癌中的应用[J].医学信息,2021,34(17):37.[doi:10.3969/j.issn.1006-1959.2021.17.010]
　FAN Li-zhuang,WANG Bo,XU Ai-lan,et al.Biological Characteristics of Circulating Free DNA and its Application in Breast Cancer[J].Journal of Medical Information,2021,34(01):37.[doi:10.3969/j.issn.1006-1959.2021.17.010]

更新日期/Last Update: 1900-01-01